Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump out unwanted or toxic substances, will announce new results from human trials of its lead compound, LIM-0705, at the 23rd International Congress of the Transplantation Society in Vancouver, Canada, in an oral presentation on August 19, 2010. The results will be presented by Dr. Daniel C. Brennan, Professor of Medicine and Director of Transplant Nephrology at Washington University School of Medicine in St. Louis.
“We are excited to begin planning for our Phase 2a study in early 2011.”
LIM-0705 is a small molecule that stimulates lipid transport. It is in development as an adjuvant therapy alongside tacrolimus, a calcineurin inhibitor used as an immunosuppressant for transplant surgery. Although tacrolimus is the gold standard in preventing solid graft rejection, it produces unwanted effects in the pancreas, brain, and kidneys which negatively impacts graft and host survival. LIM-0705 is designed to protect tissues against tacrolimus's untoward effects while preserving its anti-rejection activity.